Fitusiran prophylaxis in severe haemophilia without inhibitors
- PMID: 37003277
- DOI: 10.1016/S2352-3026(23)00057-1
Fitusiran prophylaxis in severe haemophilia without inhibitors
Conflict of interest statement
VJ-Y has received honoraria for consulting from Takeda, Bayer, BioMarin Pharmaceutical, CSL Behring, Grifols, NovoNordisk, Sobi, Sanofi, Spark Therapeutics, Roche, Octapharma, and Pfizer, and funds for research from Takeda, Bayer, Grifols, NovoNordisk and Roche. MTÁ-R has received honoraria for consulting from Takeda, Bayer, BioMarin Pharmaceutical, CSL Behring, Grifols, NovoNordisk, Sobi, Roche, Octapharma, and Pfizer, and funds for research from Takeda, Bayer, Grifols, Novo Nordisk and Roche.
Comment on
-
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.Lancet Haematol. 2023 May;10(5):e322-e332. doi: 10.1016/S2352-3026(23)00037-6. Epub 2023 Mar 29. Lancet Haematol. 2023. PMID: 37003278 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
